ANTIPHOSPHOLIPID SYNDROME (APS)
Clinical trials for ANTIPHOSPHOLIPID SYNDROME (APS) explained in plain language.
Never miss a new study
Get alerted when new ANTIPHOSPHOLIPID SYNDROME (APS) trials appear
Sign up with your email to follow new studies for ANTIPHOSPHOLIPID SYNDROME (APS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
Disease control OngoingThis early-phase trial tests an investigational biologic called EA5 in adults with antiphospholipid syndrome (APS) who have had two or more blood clots despite standard blood-thinning therapy. The study enrolls about 12 participants and gives EA5 by intravenous infusion followed …
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control ENROLLING_BY_INVITATIONThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC